AbbVie Lowers FY2026 Adjusted EPS Guidance To $13.76-$13.96/Share, Q3 To $3.73-$3.77/Share, On $216M Acquired R&D And Milestone Expense

Loading news article.

AbbVie Lowers FY2026 Adjusted EPS Guidance To $13.76-$13.96/Share, Q3 To $3.73-$3.77/Share, On $216M Acquired R&D And Milestone Expense | WAPE

Article summary